article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

3 With greater scientific understanding of cancer, the industry has made significant progress in developing innovative medicines to help patients. However, access to these medicines is not close to meeting patient demand, creating inequalities in the health prospects of those diagnosed with cancer. 1,2 In the EU, an estimated 2.7

article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. Towards the end of 2023, one sensed an emerging interest from Big Pharma in neuroscience.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NICE backs use of Boehringer’s Ofev in IPF from diagnosis

pharmaphorum

Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim’s Ofev, following new guidance from health technology assessment agency NICE. The NHS should make Ofev available within 90 days of the announcement by NICE, which means in mid-March 2023.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

1,2 Moreover, except for countries such as Czechia, Denmark and Germany, the cost of these medications is borne by the patient, rather than national insurance or healthcare systems. This will lead to a higher proportion of these medicines becoming licensed, benefitting a larger number of patients. 2023 Mar 4;16(3):257-66.

Medical 79
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

In this exclusive webinar, Dr. Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs.

article thumbnail

Efficacy of novel drug proven in MDD study

European Pharmaceutical Review

The data “are compelling, particularly the significant improvements observed in both depressive and anhedonic symptoms,” stated Dr Roger S McIntyre, FRCPC, Professor of psychiatry and pharmacology, University of Toronto and Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.

article thumbnail

Otsuka and Lundbeck’s sNDA for Rexulti gains US FDA approval

Pharmaceutical Technology

Rexulti has become the first and only pharmacological treatment to receive approval for this indication in the US. The regulator accepted and gr anted priority review for the sNDA in January 2023. We look forward to offering this first FDA-approved treatment option to address this significant unmet need for patients.”